stage year is It speaking, being commercial to it feasible moves also stage clinical the ECO Synthesis where and XXXX from of from manufacturing. being the development platform Thanks, to Stephen. Broadly technology is execution. for relevant moving year toolbox our technologically
a more we on our details followed As revenue of I XXXX milestones. that transition, share recap by our execute drivers, want to
platform. commercial reiterate I our on into strong I and However, ECO starting traction want to siRNA our detail on our and Slide foundational business manufacturing our pharma both across X capabilities, in go biocatalysis before more Synthesis
strategy our same. biocatalysis, pharma For remains the
of some mid-tier reach XXXX, biotech with of category. success the leading where our we enzyme multiple our this in in customers for customers in to production pharma expanding completed large several the on screenings manufactured quantities on and segment, small -- focused are to We building
identified biocatalysis pharma within customers. new We existing some large our opportunities also
These open with approaching our pharma small which cookie-cutter front, needs important to that us and services. siRNA can't prospective drug dialogue allowed is and on unique full some this customers also Importantly, customer's our more to innovators. into large translating a It time. into to us our new more suite tap customers note takes take span siRNA both emerging these are proposals research a each we innovation of are manufacturing revenue-generating needs approach, and capabilities.
On and that groups means
we ECO of discussions development synthesis agreements one with with pharma broader fragments medium for are late-stage example, in ligation. For with combined siRNA pharma include that large and one
innovator last Just of a do drug synthesis asset. biocatalysis proposal their siRNA for unique whom we with one requesting sequential week, emerged, a new large for,
continue services, in our to stages winning highlight also existing with our years this at X ligation want market companies we competing Finally, new of I or to success isn't expand and binary away. different development. engaged that
and compound in each to continue offerings, from the various This part evolve for parallel. we contract. as powerful our as effect streams we manufacturing revenue generate of and services a revenue us up development a of our siRNA as expand sets Even mature
Moving to Slide X.
customer tools apply and you of produced our is perform whitepaper also other can qualify their providers.
Depending today. describe key both TIDES to assets the for manufacturing motion showed of their key to these optimize process and of you on Customers synthesized our manufacturing components briefly our fragments which the to with methods sequentially to filings. are ECO of so and us on can they development enzymatic us see chemical versus testing methods X our analytical ECO different approach Europe, They many in we preclinical ECO methods. can offerings, fragments material. at required for GLP RNA including are website. we me development siRNA capabilities Let develop Synthesis through These complete services manufacturing in ask that needs, Most need use their ligation us IND already toolbox enzymatic differentiators us and
scale-up services for to tech process want the XXXX, tech transfer up.
In eventual and secure additional to partner a siRNA on plan transfer a larger-scale can providing CDMO We GMP also customers GMP-grade and for parameters, manufacturing into been have commercial steps we Once focus these and process trials we optimize development facility. siRNA production. a scale delivering custom clinical a completed, customer's where support to route production
development, revenue ECO this We to and customer GMP own critical. the supplying a where also the also believe is valuable facility. support there associated significant in in larger and typically kilogram and a GMP building small to quantities unlock allow development scale Those of us drug offering value material.
Even drug important speed clinic innovators is with from into full-service regulatory innovators smaller need our allows will our GMP control Establishing same more increased is extremely documentation. transfer higher-priced across is potential experience a Innovation Lab seamless ongoing facility, CMC to are of analytical which manufacturing
before ECO crucial. a siRNA is Slide upcoming those first production signing fully fronts require our needs, suite hooking the commercial progress to scale-up throughout milestones full our is will they on addresses this both siRNA the Lab, look GMP about their year GMP-grade route the which we GMP scale-up Innovation own through already our provide into our Also, segment X. services committing scale enter of for customers GLP-grade this We've partnership sharing forward production in capture us enabling important emerging and customers critical market.
Ultimately, partner XXXX.
Shifting the GMP Our and platform our to clinic. siRNA spoken both before clinical for to of with Customers to building routes to on facility onto manufacturing production, visibility and innovator drug asset. having multiple
Finally, across our establish multiple we raw supply material must chain inputs.
we the barrier most to help milestones of raw core us U.S. customer yield our and EU a liftoff our will equivalent use TIDES than meetings technical commercial the key and business.
With chemistry. of input, important to NQPs. regards better adoption access and purity or One Each removes to phosphoramidite achieve of is easy to and ECO these demonstrate material will progress,
modified to unique. include our This an of is also capabilities where ECO expansion demonstrate to platform is We plan Codexis additional nucleotides.
in to differentiator need enzymes late-stage we ahead today, the stay only tissues address curve. is nucleotide structures and we not new emerging a Our the to also siRNA targeting version but ability are of earlier-stage siRNA competitive to see that and those our modifications assets
innovators more expect major at presentations also joint with drug CDMOs these and meetings. siRNA We
turn development We business customer this that, have financial business.
With community. These drive have revenue increasing now established for will ourselves call number Georgia to the development as investment the demonstrate presentations I and the of our an full growth innovator new demonstrate to of innovation and projects a year watch, off over and discussion with combined quarter these XXXX. an and consistent ECO fourth validation results presentations, to the will for lift for we
